Several articles focus on new achievements by scientists in the study of disease biomarkers!

In this article, xiao compiled a number of important research results, focusing on scientists in the study of disease biomarkers to share with you! Photo credit: Pixabay/CC0 Public Domain: Clin Epigenet: Special biomarkers in father's semen or directly related to the risk of autism in offspring Doi:10.1186/s13148-020-00995 Now researchers have identified specific biomarkers in human sperm that may reveal the tendency of male offspring to develop autism spectrum disorders, which have pre-mesogenetic properties that mean they can be involved in changes in molecular factors that regulate genomic activity (such as gene expression that does not rely on DNA sequences) and can be passed on to future generations.
In a recent study published in the international journal Clinical Epigenetics, scientists from Washington State University and others identified specific genomic characteristics called DNA methylation regions in semen samples of children with autism at home;
researcher Michael Skinner says these characteristics can now be used to assess whether a man inherits his autism traits to future generations, and to help us identify factors that contribute to autism in the body.
The rate of autism spectrum disorders has risen sharply from 1/5,000 in 1975 to 1/68 in 2014; while increased diagnosis and awareness may explain some of these changes, many researchers believe that the increase in autism rates over the past two decades may be due to environmental and molecular factors, and previous studies have shown that offspring may inherit autism from their parents and that fathers are more likely than their mothers to relay autism.
: Scientists identify new potential biomarkers or are expected to help develop individualized cancer therapies doi:10.1158/0008-5472.CAN-20-0957, an international journal In a study on Cancer Research, scientists from institutions such as Duke-Singapore National University School of Medicine found a potential way to predict which patients would react to cancer therapy that blocks Wnt signals, such as ETC-159, a new drug developed in Singapore, that could help scientists develop new, individualized cancer therapies.
Wnt protein is an important signaling molecule that helps surrounding cells communicate with each other, however, cancer occurs when the protein is produced excessively; Wnt protein is involved in the onset of a variety of common cancers, including colorectal cancer, breast cancer, leukemia, and pancreatic cancer, many mutations can induce the emergence of Wnt overactive, and finding reliable biomarkers has been a challenge for scientists.
, the researchers identified a new biomarker called RNF43, which can change in a particular type of Wnt-dependent cancer.
JBC: Scientists identify new biomarkers that indicate cardiovascular disease doi:10.1074/jbc. Ra120.014183 In a study published in the international journal Journal of Biological Chemistry, scientists from the University of Technology and others identified new biomarkers of cardiovascular disease through research; The key role played by peptide peptidease 3 (DPP3, dipeptidyl peptidase 3) in the blood pressure-regulating renin-angiotensin system may provide new clues and ideas for the development of new treatments for cardionephropathy.
researchers say the nephrine-angiotensin system (RAS) activates binotenin II when the body has low blood pressure, a hormone that induces blood vessel contractions and promotes blood pressure to rise again, while enzyme-like DPP3 is significantly involved in the metabolism of angiotensin II.
Peter Macheroux said: 'For example, we all know that the level of DEP3 in the blood of patients with heart attack, blood-moderate or acute kidney injury may increase mortality, but researchers know very little about the physiological function of DPP3, and for this reason, they looked at the molecular mechanisms of DEP3 affecting RAS.
: Sci Rep: Biomarkers can be used to detect brain damage doi:10.1038/s41598-020-69865-4 Recently, by Asia A scientific team led by the University of Arizona and the City of Hope Institute for Translational Genomics (TGen) has identified a new family of biomarkers through proteomics and metabolomic analysis that can help treat tens of millions of patients with brain damage and have the potential to prevent severe long-term disability.
the results were published recently in the journal Scientific Reports.
estimates that 69 million people worldwide suffer from brain trauma (TBI) each year, including at least 3 million in the United States, resulting in nearly 288,000 hospitalizations, 56,800 deaths and 90,000 permanent disabilities.
practical application of this study is the effectiveness of a brain injury treatment called RIC (remote ischemic conditioning).
Pirarotte's team used mouse models and advanced mass spectrometrical analysis tools to analyze proteins and metabolites to identify biomarkers that showed RIC effectiveness, as well as other biomarkers that could be used to measure the presence of damage.
: Clin Cancer Res: New Results! Scientists identify new biomarkers that can indicate poor prognosis for endometrial cancer patients doi:10.1158/1078-0432.CCR-19-4088, a study published in the international journal Clinical Cancer Research In the study, scientists from the Queensland University of Science and Technology and others found new biomarkers that indicate poor prognosis for endometrial cancer, a new type of cancer biomarker and diagnostic method that can help effectively diagnose tumor types that are prone to spread and recurrence, helping researchers treat patients early and block cancer cells from attacking other parts of the body.
, a new biomarker, could help researchers develop new therapies that precisely target and kill cancer cells before they spread, says researcher Pamela Pollock. To specifically detect genetic mutations that cause malignant endometrial and uterine cancer, this biomarker is based on mutations in the FGFR2 gene (Fibroblast Growth Factor Receptor 2, fibroblast growth factor receptor), which is expressed in 40 percent of the 386 patient tumor samples studied in this study.
FGFR2 gene mutations are directly related to the shortening of survival and disease-free survival in a significant number of female patients, and in earlier studies, researchers found that FGFR2 mutations were able to turn on protein expression all the time, while recent studies have found that researchers have found a way to Turning on a new method of expression of FGFR2, the researchers believe that a mutation called FGFR2c may be used to adjust the prognosis of endometrial cancer patients and as a predictive biomarker to indicate whether tumors are resistant or sensitive to FGFR inhibitors.
image Source: medicalxpress.com BJBMS: Identification of independent biomarkers doi: 10.17305/bjbms.202 indicating the prognosm of stomach cancer 0.4620 Although scientists have made several advances in the diagnosis and treatment of stomach cancer in recent years, it is still an important public health issue, so in addition to the classic method, scientists need new biom molecules to help predict the prognosis of stomach cancer and develop new targeted therapies.
, scientists from Turkey's Feirat University identified a new independent prognosm index for stomach cancer in a study published in the international journal Bosnian Journal of Basic Medical Sciences.
researchers say the P2X7 complex is a special molecule that is thought to play a number of important roles in inflammatory events and cancer progress, and that the subject is located on the cell membrane and increases its level in many types of cancer.
Previously, researchers found that P2X7 subjects may be biomarkers of adverse prognostics of a variety of malignant tumors, such as pancreatic, colorectal and kidney cancers, but after recent studies of cancer cell line, scientists have found that P2X7-like antagonists are effective in slowing tumor growth, but no detailed clinical studies have been conducted to investigate the effects of P2X7 on the prognostic effects of P2X7 on the treatment of stomach cancer patients.
: Scientists have successfully identified 1,178 biomarkers or are expected to help predict disease progression in prostate cancer patients doi:10.1038/s41591-019-0579-z In a study published in the international journal Nature Medicine, scientists from the University of California and other institutions identified 1,178 biomarkers in the male genome that could help effectively predict the growth of prostate cancer in the male body, suggesting that clues to the progression of prostate cancer in men may be in their genetic DNA. In the
article, the researchers focused on a biological process called DNA methylation, in which DNA methylated cells turn genes on or off to promote natural processes of normal physiological changes, and DNA methylation begins when special chemical groups (methyl groups) are added to key parts of DNA that control cell function, such as protein production, which often blocks DNA methylation when it forms to help cancer cells grow and spread by turning cell function on and off.
: Scientists have discovered a new biomarker for type 1 diabetes, doi:10.1007/s00125-019-04980-0 Recently, researchers from the Turku Center for Biological Sciences in Finland found a new biomarker in the blood that indicates type 1 diabetes.
may help to understand the early pathogenesis of the disease.
the highest incidence of type 1 diabetes among children under 15 years of age.
, in many developed countries, the prevalence of the disease among children is increasing.
using the latest metabolomic methods, researchers at the Turku Center for Biological Sciences found changes in metabolites in the blood prior to the emergence of islet autoantibodies.
findings may be important for finding early markers of type 1 diabetes and understanding the pathogenesis of the disease.
in current clinical practice, islet autoantibodies are the first detectable pathogenesis.
, however, it may be too late for autoantibodies to be detected to prevent the occurrence and development of diabetes.
: MicroRNA methylation may act as a powerful biomarker for cancer: 10.1038/s41467-019-11826-1 Scientists from Osaka University have found in a study published in the international journal Nature Communications A new method to distinguish between early pancreatic cancer patients and healthy people may help develop new methods for early diagnosis of pancreatic cancer; molecular levels associated with genetic function, such as microRNA, are key indicators of cancer-related abnormal activity, but researchers aren't sure how different molecules are altered in cancer cells, and now researchers have developed a new way to effectively distinguish between cancer tissue and non-cancerous tissue.
researchers say the rate of methylation in microRNA can effectively distinguish cancer patients from healthy individuals; microRNAs can exhibit abnormal expressions in cancer tissue and are stable in body fluids, so they can act as useful biomarkers to indicate cancer occurrence; although researchers can measure RNA expression levels microRNAs, however, lack the sensitivity and accuracy of technology, especially since microRNAs are based on the assumption that targets can be identified and regulated whether they are methylated or not, their role actually changes with the different methylation states, which researchers want to solve through research.
"10" JCI Insights: New biomarkers can diagnose severe kidney allergic reactions doi:1 0.1172/jci.insight.127456 A recent study by medical researchers at Johns Hopkins University identified two protein biomarkers in urine that could one day be used to better diagnose acute interstitrin nephritis (AIN).
AIN is an undiagnosed but treatable kidney disease that can impair kidney function in the short term.
, if left unalted, can lead to permanent damage or kidney failure.
the findings were published in the journal JCI Insights.
acute interstitrinal nephritis is a condition characterized by inflammation and swelling of the kidney tubes, the kidneys